A Study of MK-1084 in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)
Phase 1
58
about 8 months
18–80
3 sites in AZ, FL, TX
About this study
This trial is testing how MK-1084 affects the body over time. Researchers are measuring MK-1084 levels to understand its behavior. They also want to assess the safety of MK-1084 in people with liver problems and determine if they can tolerate it.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take MK-1084
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Apparent Clearance (CL/F) of Calderasib, Apparent Terminal Half-life (t1/2) of Calderasib, Maximum Observed Drug Concentration (Cmax) of Calderasib, Time to Maximum Observed Drug Concentration (Tmax) of Calderasib
Secondary: Number of Participants Who Discontinue Study Due to an AE, Number of Participants Who Experience an Adverse Event (AE)